Key Takeaways
- A fresh embryo transfer happens in the same cycle as egg retrieval. A frozen embryo transfer (FET) happens in a later cycle after embryos have been vitrified (rapidly frozen).
- FET now has equivalent or better live birth rates than fresh transfer in most patient groups, according to multiple large RCTs.
- FET is clearly preferable for PCOS patients, high responders, and anyone at risk of OHSS.
- Fresh transfer may still be appropriate for normal responders with optimal endometrial preparation.
- Vitrification (rapid freezing) has largely solved the earlier problem of embryo survival — modern frozen embryo survival rates are 95%+.
- FET adds approximately Rs 25,000–50,000 to the total cycle cost (frozen embryo storage + FET cycle medication and monitoring).
When you have embryos ready, the first big question is: transfer now (fresh) or freeze them all and transfer in a later cycle (frozen)?
A few years ago, fresh transfer was the default. Today, the pendulum has swung substantially toward frozen embryo transfer (FET) for many patients. The evidence is now strong enough that "freeze all" has become standard recommendation for PCOS patients and high-responders — and increasingly being used for the general IVF population too.
This article explains exactly what the difference is, what the evidence says about outcomes, the specific situations where each approach makes sense, and the cost implications.
Key Takeaways
- A fresh embryo transfer happens in the same cycle as egg retrieval. A frozen embryo transfer (FET) happens in a later cycle after embryos have been vitrified (rapidly frozen).
- FET now has equivalent or better live birth rates than fresh transfer in most patient groups, according to multiple large RCTs.
- FET is clearly preferable for PCOS patients, high responders, and anyone at risk of OHSS.
- Fresh transfer may still be appropriate for normal responders with optimal endometrial preparation.
- Vitrification (rapid freezing) has largely solved the earlier problem of embryo survival — modern frozen embryo survival rates are 95%+.
- FET adds approximately Rs 25,000–50,000 to the total cycle cost (frozen embryo storage + FET cycle medication and monitoring).
What Is a Fresh Embryo Transfer?
In a fresh cycle, egg retrieval and embryo transfer happen in the same stimulation cycle:
- Day 0: Egg retrieval
- Day 3 or Day 5: Embryo transfer (without freezing)
The advantage: speed. You go from retrieval to transfer in 3-5 days. The uterus is already under hormonal influence from the stimulation, though progesterone support is added.
The disadvantage: the uterus may not be in optimal condition. During ovarian stimulation, high estrogen levels affect the endometrium in ways that may not be ideal for implantation. The endometrial "window of implantation" may be shifted earlier or the environment may differ from a natural cycle.
What Is a Frozen Embryo Transfer (FET)?
In a freeze-all approach:
- Day 0: Egg retrieval — all resulting blastocysts are vitrified (frozen)
- Days 1-5: Post-retrieval recovery
- Next cycle (typically 4-6 weeks later): A separate FET cycle is done with dedicated endometrial preparation
FET cycle preparation — two main approaches:
1. Medicated (Artificial) FET:
- Estrogen supplementation (oral Progynova, transdermal patches, vaginal gel) for ~12-14 days to grow the lining
- Once lining is ≥ 7-8 mm with trilaminar pattern, progesterone supplementation begins
- Embryo transfer happens approximately 5 days after progesterone starts (for blastocyst transfer)
- Estrogen and progesterone continue until 10-12 weeks of pregnancy
2. Natural Cycle FET:
- Patient's own hormonal cycle is monitored
- After natural ovulation (confirmed by LH surge and ultrasound), progesterone begins
- Blastocyst transfer 5 days after LH surge
- Better for women with regular ovulatory cycles; avoids all the medication load
3. Modified Natural FET:
- Natural cycle with a trigger shot to precisely time ovulation
- Luteal phase supported with progesterone after trigger
The Evidence: How Do They Compare?
The Major RCTs
FRESH trial (Shi et al., NEJM 2018):
- N = 782 patients with PCOS
- Freeze-all vs fresh transfer
- Live birth rate: 49.3% (frozen) vs 42.5% (fresh) — significant benefit for freeze-all
- OHSS: dramatically lower with freeze-all (1.3% vs 2.5%)
- Conclusion: For PCOS patients, freeze-all is clearly superior
COPS trial (Chen et al., NEJM 2016):
- N = 1,508 normal responders
- Freeze-all vs fresh transfer
- Live birth rates: 48.7% (frozen) vs 50.2% (fresh) — NO significant difference
- Conclusion: In normal responders, fresh and frozen are equivalent
SETI trial (Shi et al., 2020, NEJM):
- Subsequent to COPS, addressed singleton outcomes
- Frozen transfers associated with higher birthweight (potential benefit or concern for LGA — large for gestational age)
Meta-analysis (Roque et al., 2019, Fertility & Sterility):
- Pooled analysis of 11 RCTs (N = 4,031)
- FET: significantly higher live birth rate per cycle started
- FET: significantly lower OHSS risk
- FET: higher risk of hypertensive disorders of pregnancy (a concern — see below)
The Hypertensive Pregnancy Risk: FET's Notable Downside
Multiple studies have shown that frozen embryo transfers — particularly in medicated FET cycles — are associated with a higher risk of:
- Pre-eclampsia (high blood pressure in pregnancy)
- Placenta-related complications
- Large for gestational age (LGA) babies
The mechanism is debated. The current leading hypothesis: in natural cycles, there is a corpus luteum (the remnant of the ovulated follicle) that produces vasoactive substances (nitric oxide, relaxin) important for maternal cardiovascular adaptation to pregnancy. In medicated FET cycles, there is no ovulation and therefore no corpus luteum — this may impair normal placental development.
What this means in practice:
- Natural cycle FET and modified natural cycle FET appear to have lower hypertensive risk than medicated (artificial) FET
- This is an evolving area — the British Fertility Society and ESHRE are updating guidance
- IVF pregnancies from frozen transfers require appropriate antenatal monitoring for pre-eclampsia
This risk does NOT mean FET is dangerous — the absolute risk remains relatively low and the benefit in preventing OHSS and potentially improving implantation rates is real. But it's important to understand.
When Freeze-All Is the Right Choice
Clear indications for freeze-all:
Indication: PCOS or high ovarian response · Reason: High OHSS risk — hCG trigger or large follicle counts increase risk dramatically
Indication: Premature progesterone rise · Reason: Progesterone > 1.5 ng/mL on trigger day impairs fresh implantation
Indication: Inadequate endometrial thickness on retrieval day · Reason: Lining < 7 mm — wait for better cycle
Indication: Using GnRH agonist trigger · Reason: Agonist trigger creates a short luteal phase not suitable for fresh transfer
Indication: Hydrosalpinx identified · Reason: Fallopian tube fluid can impair implantation — needs treatment first
Indication: Severe uterine polyp or fibroid found · Reason: Address before transfer
Indication: Fever or illness around retrieval · Reason: Postpone for safety
Indication: Patient request · Reason: Timing, convenience, personal preference
When Fresh Transfer May Still Be Appropriate
Situation: Normal responder, low OHSS risk · Rationale: No strong reason to delay
Situation: Natural (no stimulation) or modified natural IVF · Rationale: No artificial luteal phase disruption
Situation: Adequate lining on retrieval day · Rationale: Environment ready
Situation: Patient prefers fewer cycles and delays · Rationale: Valid consideration
Situation: Cost sensitivity · Rationale: FET adds a cycle's worth of costs
For normal responders (not PCOS, AMH < 3.5, AFC < 15, < 15 eggs retrieved), the COPS trial showed fresh and frozen are equivalent. A thoughtful clinician might offer either, based on individual factors.
Embryo Freezing: How It's Done (Vitrification)
Modern embryo freezing uses vitrification — ultra-rapid freezing in which the embryo is cooled so fast (> 20,000°C per minute) that water molecules don't have time to form ice crystals. Instead, they solidify into a glass-like state.
This is a revolution over the older "slow freezing" technique, which damaged more embryos.
Vitrification survival rates: 95-98% of Day 5 blastocysts survive the freeze-thaw process at a skilled IVF laboratory. In the early days of IVF (1980s-1990s), frozen embryos were considered inferior. Today, a well-vitrified embryo is essentially unchanged.
Who vitrifies matters: Embryo survival after vitrification is highly technique-dependent. Experienced embryologists at well-equipped labs achieve 97%+ survival. Clinics with less experience may have lower rates. This is a question worth asking.
Cost Comparison: Fresh vs FET
Cost Component: Stimulation cycle · Fresh Transfer: Rs 1,00,000–1,50,000 · Frozen Embryo Transfer: Rs 1,00,000–1,50,000
Cost Component: Embryo freezing (vitrification) · Fresh Transfer: — · Frozen Embryo Transfer: Rs 15,000–30,000
Cost Component: Embryo storage (annual) · Fresh Transfer: — · Frozen Embryo Transfer: Rs 10,000–20,000 per year
Cost Component: FET cycle preparation (estrogen, monitoring) · Fresh Transfer: — · Frozen Embryo Transfer: Rs 15,000–35,000
Cost Component: Total first attempt · Fresh Transfer: Rs 1,00,000–1,50,000 base · Frozen Embryo Transfer: Rs 1,40,000–2,35,000 base
The FET cycle adds approximately Rs 40,000–85,000 in costs. However, the overall cost-per-baby may be lower with FET if success rates are higher (fewer total cycles needed).
What Happens to Frozen Embryos?
Unused frozen embryos are stored for future use. Under the ART Act 2021, embryo storage in India is regulated:
- Clinics must be licensed for cryo storage
- You own your embryos and decide their fate
- Consent must be obtained for all decisions about unused embryos
- Options: continue storage (pay annual fee), donate to another couple (with consent), donate for research, or allow to perish (not transferred)
Storage time: no regulatory limit in India, though clinics set their own policies. Many clinics store embryos for 5-10 years with annual renewal.
Questions to Ask Your Doctor
Questions to Ask Your Doctor 1. Based on my response and OHSS risk, are you recommending fresh or freeze-all? 2. What was my progesterone level on trigger day? Was there a premature rise? 3. What type of FET cycle would I have — medicated or natural? 4. What is your clinic's embryo vitrification survival rate? 5. What is the additional cost for freeze-all vs fresh transfer? 6. How long would I need to wait between retrieval and FET? 7. Is there any reason specific to my case to prefer fresh over frozen? 8. Will my pregnancy be monitored for pre-eclampsia risk after a frozen transfer?
The Bottom Line
For PCOS patients and high responders, freeze-all FET is not just better — it's the standard of care. The data is clear.
For normal responders, the evidence shows frozen and fresh transfers produce similar live birth rates. The trend in Indian and global IVF is toward freeze-all for most patients, driven by the ability to optimize endometrial preparation and dramatically reduce OHSS risk.
If your clinic is recommending a fresh transfer for a PCOS patient or a high-responder cycle, that is worth questioning. If they're recommending freeze-all for a normal responder, ask why — it may be a reasonable clinical decision, but you should understand the rationale.
The goal is always the same: the best chance of a healthy baby, in the safest way possible.
Medical Disclaimer This article is for informational and educational purposes only. Fresh versus frozen embryo transfer decisions depend on individual clinical factors and must be made with your fertility specialist. This article does not constitute medical advice. Clinical evidence in reproductive medicine evolves rapidly — consult your doctor about the most current guidance.
Join GarbhSaathi — India's independent fertility journey companion.
Get more guides like this
Honest, evidence-based IVF information — delivered to your inbox.
No spam, ever. Unsubscribe with one click.
GarbhSaathi is fully independent. We are not affiliated with any clinic, pharma company, or hospital. Our content is funded by readers, not the fertility industry. We say what we believe is true — even when it's uncomfortable for clinics.
Our Sources
ICMR, PubMed, Peer-Reviewed Research
Every article is researched using ICMR guidelines, PubMed studies, and peer-reviewed medical literature. We are assembling a formal medical advisory board — advisor names will be published once confirmed.